期刊文献+

73例乳腺癌MRP、P53、ER、PR蛋白表达及临床意义 被引量:3

Expression of MRP,P53,ER,PR Proteins in 73 Breast Cancers and their Clinical Significance
原文传递
导出
摘要 目的探讨多药耐药相关蛋白(MRP)、P53、雌激素受体(ER)、孕激素受体(PR)蛋白在乳腺癌组织中表达的特性,相关性和临床意义。方法应用SP免疫组织化学法检测73例乳腺癌标本中MRP、P53、ER、PR蛋白的表达,结合临床、病理资料进行回顾性分析。结果 MRP、P53、ER、PR在乳腺癌中的阳性表达率依次为35.6%(26/73)、69.9%(51/73)、60.3%(44/73)和56.2%(41/73),表达与患者年龄、肿瘤大小、腋窝淋巴结转移和组织学分级无显著相关性,MRP与P53之间存在显著正相关性(P<0.05),MPR与ER/PR的表达无显著性相关(P>0.05),而P53与ER/PR的表达显著相关(P<0.05)。结论乳腺癌MRP、P53、ER和PR的表达为乳腺癌的药物治疗提供了客观参考指标,对制定个体化方案和预后有一定帮助。 Objective To assess the characteristic of multidrug resistance related protein(MRP),P53,estrogen receptor(ER) and progesterone receptor(PR) proteins expression in breast cancer,and analyze their correlation and clinical significance.Methods The SP immunohistochemical technique was used to detect MRP,P53,ER,and PR proteins expression in 73 patients with breast cancer.The relationships with their clinical and pathological data were retrospectively analyzed.Results The expression rate of MRP,P53,ER,and PR proteins was 35.6%(26/73),69.9%(51/73),60.3%(44/73),and 56.2%(41/73),retrospectively.The expression of four proteins was not significantly correlated with the patient age,the tumor size,the axillary lymph node metastasis,and the history grade(P〉0.05).The significantly positive correlation was the expression of MRP and P53,ER /PR and P53(P〈0.05).No correlation was found in MRP and ER/PR(P〉0.05).Conclusion It is necessary for detecting MRP,P53,and ER/PR expressions in breast cancer to judge clinical prognosis and make personalized therapeutic plan.
出处 《中国病案》 2011年第2期21-22,共2页 Chinese Medical Record
关键词 乳腺癌 免疫组化 多药耐药相关蛋白 P53 雌激素受体 孕激素受体 Breast cancer Immunohistochemistry MRP P53 ER PR
  • 相关文献

参考文献8

  • 1Coley HM.Mechanisms and strategies to overcome chemotherapy resistance in metastatic breast cancer[J].Cancer Treatment Reviews,2008,34:378-390.
  • 2Sankpal NV,Willman MW,Fleming TP,et al.Transcriptional repression of epithelial cell adhesion molecule contributes to P53 control of breast cancer invasion[J].Cancer Res,2009,69(3):753-757.
  • 3曾爱华,何蕴韶.siRNA逆转乳腺癌多药耐药的研究[J].广东药学院学报,2006,22(2):176-178. 被引量:5
  • 4LaPensee EW,Ben-Jonathan N.Novel roles of prolactin and estrogens in breast cancer:resistance to chemotherapy[J].Endocrine-Related Cancer,2010,17(2):91-107.
  • 5Razandi M,Pedram A,Levin ER.Plasma membrane estrogen receptors signal to antiapoptosis in breast cancer[J].Molecular Endocrinology,2000,14:1434-1447.
  • 6Zampieri L,Bianchi P,Ruff P,Arbuthnot P.Differential modulation by estradiol of P-glycoprotein drug resistance protein expression in cultured MCF7 and T47D breast cancer cells[J].Anticancer Research,2002,22:2253-2259.
  • 7Shirley SH,Rundhaug JE,Tian J,et al.Transcriptional regulation of estrogen receptor-a by p53 in human breast cancer cells[J].Cancer Res,2009,69(8):3405-14.
  • 8中国抗癌协会乳腺癌专业委员会.中国抗癌协会乳腺癌诊治指南与规范(2007版)[J].中国癌症杂志,2007,17(5):410-428. 被引量:232

二级参考文献5

  • 1曾爱华,何蕴韶,李虎,王穗海.实时荧光定量PCR检测乳腺癌5种多药耐药基因的表达强度[J].陕西医学杂志,2005,34(2):135-137. 被引量:4
  • 2EIBASHIR S M,HARBORTH J,WEBER K,et al.Analysis of gene function in somatic mammalian cells using small interference RNAs[J].Methods,2002,26:199 213.
  • 3HARBORTH J,EIBASHIR S M,BECHERT K,et al.Identification of essential genes in cultured mammalian cells using small interfering RNAs[J].J Cell Sci,2001,114(24):4 557.
  • 4ZHANG L,YANG N,MOHAMED A,et al.Vector-based RNAi,a novel tool for isoform specific knock-down of VEGF and anti-angiogenesis gene therapy of cancer[J].Biochem Biophys Res Commun,2003,303(4):1 169.
  • 5FIRE A,XU S,MONTGOMERY M K,et al.Potent and specific genetic interference by double-stranded RNA in caenorhabdits elegans[J].Nature,1998,391:806.

共引文献235

同被引文献25

  • 1辛华雯,王润帮.MTT显色法快速测定实体瘤化疗药物敏感性的方法研究[J].肿瘤防治研究,1993,20(4):254-256. 被引量:26
  • 2项炜,朱贤立,赵洪洋.p53基因联合顺铂对实验性胶质瘤的治疗作用[J].中国临床神经外科杂志,2006,11(3):154-156. 被引量:2
  • 3彭爱娟,黄水香,何秀芳.三明市城区3260例妇女乳房疾病普查分析[J].基层医学论坛(B版),2006,10(12):1068-1069. 被引量:2
  • 4黄腾钦,王龙垣,马俊,张清辉.新辅助化疗治疗局部晚期乳腺癌的疗效分析[J].中国病案,2007,8(9):46-48. 被引量:1
  • 5Dizdarevic S, Peters AM. Imaging of multidrug resistance in cancer[ J]. Cancer Imaging, 2011 ( 11 ) : 1 - 8.
  • 6Marquette C, Nabell L. Chemotherapy -resistant metastat- ic breast cancer[J]. Curr Treat Options Onco, 2012(2) : 263 - 275.
  • 7Cole SP, Bhardwaj G, Gerlach JH,et al. Over expression of a novel transporter gene in a multidrug resistant human lung cancer cell line [ J ]. Science, 1992 (5088) : 1650 - 1654.
  • 8Ercan C, Diest PJ, Der Ende B, et al. P53 mutations in classic and pleomorphic invasive lobular carcinoma of the breast[J]. Cell Oncol (Dordr), 2012(2):111- 118.
  • 9Sturm I, Bosanquet AG, Hermann S, et al. Mutation of P53 and consecutive selective drug resistance in B-CLL occuras a consequence of prior DNA-damaging chemother- apy [ J ]. Cell Death and Differentiation, 2003 (10) :477 - 484.
  • 10Bahr O, Wick W, Weller M. Modulation of MDR/MRP by wild-type and mutant P53 [ J ]. Clinl Investigation, 2001(5) :643 -645.

引证文献3

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部